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men will respond to androgen deprivation  therapy for a 
finite time before ultimately progressing and succumbing to 
their disease. 
Bone targeted therapy has included bone-seeking 
radionuclides for nearly 30 years. The beta-emitting bone-
seeking radionuclides Strontium-89 and Samarium-153 EDTMP 
as well as Rhenium-186 HEDP and Rhenium-188 HEDP have 
been used to palliate pain in advanced cancer metastatic to 
bone for many years [2]. Despite clear evidence of benefit in 
palliation, these agents have never been shown to result in a 
survival benefit for patients.  
Radium-223 is the first in class alpha-emitting radionuclide 
which began clinical testing almost 10 years ago and has 
recently become licenced for the treatment of castration 
resistant pros-tate cancer (CRPC) metastatic to bone. In an 
international prospective randomised clinical trial, Radium-
223 (50kBq/kg, for 6 cycles at 4 weekly intervals) + best 
standard of care (BOS) was shown to improve overall survival 
compared to placebo + BOS in men with symptomatic, meta-
static CRPC. Radium-223 also resulted in significant 
improvement in time to symptomatic pro-gression [3].  
The rationale for combining External Beam Radiotherapy 
(EBRT) with Radium-223 in the treatment of metastatic 
prostate cancer will be discussed. In particular the potential 
for using Radium-223 along with advanced EBRT with 
‘curative’ intent in hormone naïve de novo metastatic 
prostate cancer will be described. 
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Throughout the past two decades the efforts to improve 
treatment efficacy for locally advanced head and neck 
squamous cell carcinoma (LA-HNSCC) have led to increased 
use of multimodality approaches combining surgery, 
radiotherapy (RT), and chemotherapy (CT). In fact, 
conventional RT  was associated with unsatisfactory patients’ 
outcomes, thereby a greater understanding of radiobiology 
led to the development of altered irradiation schedules, such 
as hyperfractionation (HF) and accelerated fractionation 
(AF), in the management of advanced HNSCC. Randomized 
controlled trials and meta-analyses demonstrated that for 
patients with locally advanced HNSCC, major improvements 
in loco-regional control and overall survival rates may be 
obtained by AF and HF with increased total radiation dose. 
CT represents an important component of multimodality 
treatment approach for locally advanced HNSCC. The 
combination of concurrent CT and RT (CCRT)  provides a 
substantial and statistically significant improvement in 
survival and loco-regional control, as compared to RT alone. 
CCRT has been also shown to preserve healthy tissue in 
almost two thirds of patients, without affecting survival. 
 However, despite hundreds of clinical trials in patients with 
advanced disease, there is no widespread consensus about 
patient selection for altered fractionation regimens, type of 
chemo-radiotherapy association, radiation/ chemotherapy 
dose schedule in LA-HNSCC. The state of the art of 
radiobiological models for tumor control and toxicity after 
CCRT will be presented together with methods of BED 
calculation. Model parameters will be introduced to be 
applicable to different chemotherapy schedules. The aim is 
to highlight the potential convenience of using radiobiology 
in the selection more effective treatment strategies. As 
secondary aim BED for combined CCRT with/without 
hyperthermia (HT) will be introduced to further stress the 
versatility of radiobiological concepts in predicting patient’ 
outcome and improving the efficacy of treatment strategies. 
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Particle therapy offers distinct physical properties leading to 
reduction of integral dose. For low-LET particles, biology is 
relatively comparable to photons, however, if this often cited 
sentence is correct in detail, is a matter of discussion. Albeit 
known heterogeneities and differences, altogether, the 
relative biological effectiveness (RBE) is postulated to be 
around 1.1. Proton therapy requires elaborate, large and 
expensive facilities, leading to a cost that is several times 
higher than advanced photon treatments. Treatment planning 
for particle therapy is delicate, special knowledge and 
training is necessary, and caution must be met at all steps. 
In spite of all these challenges, there is a strong rationale 
that the physical benefits of particle therapy convert into a 
clinical benefit for the patient. To date, however, no 
randomized trial has shown these benefits. For certain 
indications, the argument for proton therapy is evident, such 
as some skull base tumors, or pediatric patients, when timely 
proton treatment is available.  
Currently, with many centers worldwide, reserach foci are 
ongoing in different disease groups, as well as in terms of 
further pre-clinical assessment, to define the therapeutic 
window or proton therapy. 
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The first Scandinavian Proton Centre, Skandionkliniken, is 
planned to treat its first patient in June 2015; a facility 
owned by the seven regions with university hospitals. 
Patients will be referred to Skandionkliniken through these 
hospitals utilising “distributed competence” [1]. The patients 
will be prepared for treatment at their “home centre”; 
immobilisation, CT-scanning and treatment planning will be 
performed at the university hospital. All treatment plans will 
be reviewed at joint teleconference meetings [2] prior to the 
treatment start. The patient and any individual 
immobilisation device will be sent to Skandionkliniken for 
treatment. Skandionkliniken will be a “spot scanning only” 
facility.  
